Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tango Therapeutics (TNGX) Liabilities and Shareholders Equity (2020 - 2025)

Tango Therapeutics (TNGX) has 6 years of Liabilities and Shareholders Equity data on record, last reported at $398.7 million in Q4 2025.

  • For Q4 2025, Liabilities and Shareholders Equity rose 25.97% year-over-year to $398.7 million; the TTM value through Dec 2025 reached $1.1 billion, down 23.04%, while the annual FY2025 figure was $398.7 million, 25.97% up from the prior year.
  • Liabilities and Shareholders Equity reached $398.7 million in Q4 2025 per TNGX's latest filing, up from $210.1 million in the prior quarter.
  • Across five years, Liabilities and Shareholders Equity topped out at $530.1 million in Q3 2021 and bottomed at $167.5 million in Q2 2021.
  • Average Liabilities and Shareholders Equity over 5 years is $368.9 million, with a median of $400.6 million recorded in 2023.
  • Peak YoY movement for Liabilities and Shareholders Equity: surged 214.84% in 2021, then plummeted 40.37% in 2025.
  • A 5-year view of Liabilities and Shareholders Equity shows it stood at $500.2 million in 2021, then fell by 12.73% to $436.5 million in 2022, then dropped by 7.77% to $402.6 million in 2023, then fell by 21.38% to $316.5 million in 2024, then grew by 25.97% to $398.7 million in 2025.
  • Per Business Quant database, its latest 3 readings for Liabilities and Shareholders Equity were $398.7 million in Q4 2025, $210.1 million in Q3 2025, and $237.9 million in Q2 2025.